Symeres Strengthens US Foothold with Exemplify Buy

27.10.2022 - Dutch CDMO Symeres has acquired Exemplify Biopharma, a US-based contract research organization (CRO) based in Cranbury, New Jersey, USA. The deal further strengthens Symeres’ foothold in the US, where it already generates about 50% of its revenues.

Exemplify provides integrated end-to-end small molecule chemistry manufacturing and controls services to pharma and biotech partners, offering expertise and consultancy in process & analytical chemistry and formulation development. The company, which has 20 employees, will remain under the management of its co-founders CEO Yadan Chen and chief scientific officer Paul O’Shea.

Eelco Ebbers, co-founder and CEO of Symeres, commented: “Exemplify has an excellent track record of supporting the development needs of North American biotech companies through their experience and outstanding laboratory-based science. This acquisition, following the addition of Organix earlier this year and our investment plans for all of our R&D facilities, is a further tangible demonstration of Symeres’ strategy of building a leading mid-sized transatlantic pharmaceutical R&D service provider for our clients around the world.”

Symeres took over Organix and its 47 employees in April this year. Located in Woburn, Boston, Massachusetts, Organix is an organic chemistry services provider that specializes in lipids addressing the mRNA therapeutics and vaccines market. Its revenues are mostly generated from selling specialized and complex organic chemistry research services to biopharma clients.

Headquartered in Groningen, Symeres has about 600 employees across sites in Nijmegen and Weert, the Netherlands, Prague in the Czech Republic, Oulu in Finland, and in the US. It has been majority owned since April 2021 by Keensight Capital, a European growth buyout firm focusing on technology and healthcare.


Author: Elaine Burridge, Freelance Journalist